Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: a randomised multicentre trial. CHART Steering Committee.
about
Targeting Notch to overcome radiation resistanceNovel approaches of chemoradiotherapy in unresectable stage IIIA and stage IIIB non-small cell lung cancer2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancerDefinitive radiotherapy in locally advanced non-small cell lung cancer: dose and fractionationChallenges in the treatment of early non-small cell lung cancer: what is the standard, what are the challenges and what is the future for radiotherapy?The analysis, interpretation, and presentation of quality of life data.CT virtual simulation.Management of lung cancerRole of multimodality treatment for lung cancer.Innovative treatment strategies in locally advanced and/or unresectable non-small cell lung cancer.The role of induction therapy in the management of resectable non-small cell lung cancer.Immediate versus delayed palliative thoracic radiotherapy in patients with unresectable locally advanced non-small cell lung cancer and minimal thoracic symptoms: randomised controlled trialNon-small cell lung cancer and CHART (continuous hyperfractionated accelerated radiotherapy)--where do we stand?Lung cancer--where are we today? Current advances in staging and nonsurgical treatment.Helical tomotherapy: an innovative technology and approach to radiation therapy.Lung cancer 5: state of the art radiotherapy for lung cancerImage-guided conformal radiation therapy planning and delivery for non-small-cell lung cancer.A matter of timing: identifying significant multi-dose radiotherapy improvements by numerical simulation and genetic algorithm search.A phase I trial of the HIV protease inhibitor nelfinavir with concurrent chemoradiotherapy for unresectable stage IIIA/IIIB non-small cell lung cancer: a report of toxicities and clinical response.Using fluorodeoxyglucose positron emission tomography to assess tumor volume during radiotherapy for non-small-cell lung cancer and its potential impact on adaptive dose escalation and normal tissue sparing.Experience with dose escalation using CHARTWEL (continuous hyperfractionated accelerated radiotherapy weekend less) in non-small-cell lung cancer.Population screening for lung cancer using computed tomography, is there evidence of clinical effectiveness? A systematic review of the literature.Carcinoma of the bronchus 60 years laterStrategies for enhanced radiation delivery in patients with lung cancer.Radiotherapy physics research in the UK: challenges and proposed solutions.Gemcitabine and carboplatin: is this the best combination for non-small cell lung cancer?NCI-RTOG translational program strategic guidelines for the early-stage development of radiosensitizers.Physical and psychological symptoms of quality of life in the CHART randomized trial in head and neck cancer: short-term and long-term patient reported symptoms. CHART Steering Committee. Continuous hyperfractionated accelerated radiotherapy.Accelerated hyperfractionation (AHF) compared to conventional fractionation (CF) in the postoperative radiotherapy of locally advanced head and neck cancer: influence of proliferation.Accelerated regrowth of non-small-cell lung tumours after induction chemotherapy.Protocol for the isotoxic intensity modulated radiotherapy (IMRT) in stage III non-small cell lung cancer (NSCLC): a feasibility study.Survival from lung cancer in England and Wales up to 2001Phase III study of cisplatin with pemtrexed or vinorelbine plus concurrent late course accelerated hyperfractionated radiotherapy in patients with unresectable stage III non-small cell lung cancer.High-dose accelerated hypofractionated three-dimensional conformal radiotherapy (at 3 Gy/fraction) with concurrent vinorelbine and carboplatin chemotherapy in locally advanced non-small-cell lung cancer: a feasibility study.IDEAL-CRT: A Phase 1/2 Trial of Isotoxic Dose-Escalated Radiation Therapy and Concurrent Chemotherapy in Patients With Stage II/III Non-Small Cell Lung Cancer.Dose escalation of accelerated hypofractionated three-dimensional conformal radiotherapy (at 3 Gy/fraction) with concurrent vinorelbine and carboplatin chemotherapy in unresectable stage III non-small-cell lung cancer: a phase I trial.Functional image-based radiotherapy planning for non-small cell lung cancer: A simulation study.Challenges in optimizing chemoradiation in locally advanced non small-cell lung cancers in India.State-of-the-art lung cancer radiation therapy.Radiation-induced esophagitis in lung cancer.
P2860
Q26771701-E4EEDCA9-9528-4D03-A80D-FD4865B36BA0Q26827571-E5F76213-D216-42ED-96E5-443359533BECQ27002509-5EBD5612-777A-4A0C-9048-D2F586DB0506Q27027626-5F3F5D00-D353-4958-AC3A-0D9FDB668AF6Q28083924-293CC26F-788C-44E2-A55D-E87B04BB88C0Q30913610-FED1B4EB-A972-436D-973C-985FF6A49CA7Q32071326-66B2EFA4-944F-4116-A354-8CEF9204CB95Q33583714-D650B96D-210E-437F-9A7D-903B433D6685Q33829263-ABE554C3-F6A4-4EF5-9B54-44EF508DCE01Q33877442-57684072-6319-4DA4-B387-C7DCAF504320Q33877447-4BB13921-4CB8-4AA6-A76E-43BD9CCD7159Q33932354-25844359-54F0-420F-A9D7-A25485B255DAQ34150508-5699E31B-2E9E-424A-AEAB-D9C29FD65947Q34982142-FDF734C0-8237-4429-9B69-728F98B9F9BDQ35081134-A736365E-E506-4D09-B493-CC4204656597Q35120111-B36A529B-C6A0-4CE4-8D42-87D3C6E42F48Q35198440-16074433-B663-4495-AF63-BCBE03E88D94Q35474386-25853E90-1DD0-4CAA-87DC-4E954F6DE438Q35848165-44F49FB1-09A0-4CC1-A453-48444611FB5EQ36054772-434DBCCB-38F3-4511-B45F-F30B2D537887Q36115655-F25025C0-9F3A-4145-B485-02106CA326F9Q36203194-B02C2B5E-FA7E-41D2-A1E0-BFD7371B92D7Q36225309-3C0E4408-C87E-4CD1-81F3-13A0FE55485FQ36316678-9FCDFDF9-09DB-4455-8DD4-10F6C8E00E28Q36325879-BA21A7F4-9305-4194-9699-4390A32BDE4EQ36381261-91BDF316-3A0C-4636-A31D-0EBA3D4DB5FDQ36507559-0CC367D9-D32D-490D-8E38-ED67876A72E6Q36641010-767BC9E2-0753-40D0-9D99-FD9D012A1E1AQ36644097-B08D306C-66C6-4631-B4B7-8DAC175F553FQ36673537-91A1B37A-F2B8-4C57-9231-3EB478D89D1AQ36818897-F0D0B4BA-768C-494E-8EB0-D76264CB7408Q36917779-CF4FDBC2-F622-4005-B476-3A7E40735B99Q36946823-7BC03F53-F780-49DD-B981-4EA66AC6D764Q37114850-08FF1829-BCB9-4E63-A7FA-708E725E03EEQ37123650-60FA8901-A675-4032-B4C7-C6C35B2B4C97Q37152509-E5019E63-96FF-4AFD-A5DF-2101F107F136Q37369904-2C71FC77-0C12-48EE-9567-3F7FFDB74DE3Q37467273-606492A2-73A7-4379-A49C-34DBB67CFB1DQ37614564-616C51BD-187E-4318-B6FA-F69E211D0179Q37643563-061AA055-673A-4C87-8731-575E501CAD15
P2860
Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: a randomised multicentre trial. CHART Steering Committee.
description
1997 nî lūn-bûn
@nan
1997 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
name
Continuous hyperfractionated a ...... ial. CHART Steering Committee.
@ast
Continuous hyperfractionated a ...... ial. CHART Steering Committee.
@en
type
label
Continuous hyperfractionated a ...... ial. CHART Steering Committee.
@ast
Continuous hyperfractionated a ...... ial. CHART Steering Committee.
@en
prefLabel
Continuous hyperfractionated a ...... ial. CHART Steering Committee.
@ast
Continuous hyperfractionated a ...... ial. CHART Steering Committee.
@en
P2093
P1433
P1476
Continuous hyperfractionated a ...... ial. CHART Steering Committee.
@en
P2093
P304
P356
10.1016/S0140-6736(97)06305-8
P407
P577
1997-07-01T00:00:00Z